My goals of my research program are summarized as follows:
1. To study aspects of women’s health to enhance our understanding of specific issues in women’s health and improve the quality of care of women.
2. To evaluate interventions to identify patients at high risk for osteoporotic fractures and to enhance the care of patients with osteoporosis.
3. To develop innovative techniques to influence pharmacists’ practice specifically in the areas of women’s health and osteoporosis.
Selected Publications (*corresponding author)
Sydora B, Fast H, Campbell S, Yuksel N, Lewis JE, Ross SJ*. Use of the Menopause-Specific Quality of Life (MENQOL) questionnaire in research and clinical practice: a comprehensive scoping review. Menopause 2016;23(9):1038-51.
Schindel TJ, Yuksel N, Breault R, Daniels J, Varnhagen S, Hughes CA*. Perceptions of Pharmacists' Roles in an Era of Expanding Scopes of Practice. Res Social Adm Pharm 2016;Mar 16 (Epub ahead of print)
Sadoswki CA, Lyder C, Yuksel N* Beliefs and current practices of pharmacists with bisphosphonate use for osteoporosis in patients with renal insufficiency. Can J Hosp Pharm 2016;69(1):14-22.
Croden J, Ross S, Yuksel N, Sydora BC*. A survey of the availability in Canadian pharmacy chains of over-the-counter natural health products for menopause symptoms. BMC Complement Altern Medicine 2015;15(1): 86. doi: 10.1186/s1290601506085.
Shifren JL*, Gass MLS for the NAMS Recommendations for Clinical Care of Midlife Women Working Group (note: part of working group). The North American Menopause Society Recommendations for Clinical Care of Midlife Women. Menopause 2014;21(10):1-25.
Wang E, Marnoch C, Khurana R, Sia W, Yuksel N*. Hemorrhagic complications of peripartum anticoagulation: A Retrospective Chart Review. Obstet Med 2014;7(2):77-83
Guirguis LM, Makowsky M*, Hughes C, Sadowski C, Yuksel N. How have pharmacists in different practice settings integrated prescribing privileges into practice in Alberta? A Qualitative Exploration. J Clin Pharm Ther 2014 Aug;39(4):390-8.
Hughes C, Makowsky M, Sadowski C, Schindel T, Yuksel N, Guirguis LM*. What prescribing means to pharmacists: A qualitative exploration of practicing pharmacists in Alberta. Int J Pharm Pract. 2014;22:283-291.
Makowsky M, Guirguis LM*, Hughes C, Sadowski C, and Yuksel N. Factors influencing pharmacists’ adoption of prescribing: qualitative application of the diffusion of innovations theory. Implement Science 2013; 8:109: 1 – 11.
Siyam T, Yuksel N*. Beliefs about Bioidentical Hormone Therapy: A cross-sectional survey of pharmacists. Maturitas 2013;74(2):196-202.
Schindel TJ*, Kehrer JP, Yuksel N, Hughes CA. University-based continuing education for pharmacists: Doing what universities do best. Am J Pharm Educ 2012; 76(2): Article 20.
Yuksel N* Practice spotlight: Pharmacist practice in an outpatient menopause clinic. Can J Hosp Pharm 2012;65(1):43–44.
Yuksel N*, Tsuyuki RT, Majumdar SR. Predictors of bone mineral density testing in patients at high risk of osteoporosis: secondary analyses from the OSTEOPHARM randomized trial. J Clin Densitometry. 2012:15(1):61-6.
Guirguis L*, Cooney D, Dolovich L, Eberhart F, Hughes C, Makowsky M, Sadowski C, Schindel T, Yuksel N. Exploring pharmacists’ understanding and adoption of prescribing in two Canadian jurisdictions: design and rationale for a mixed methods approach. Can Pharm J 2011;144(5):240-244.
Yuksel N*. Pharmacy course in Women’s and Men’s Health. Am J Pharm Educ 2011; Aug 10;75(6):119
Chubaty A,, Schuurmans N, Shandro MT, Yuksel N*. Practice Patterns With Hormone Therapy After Surgical Menopause. Maturitas 2011;69:69-73.
Yuksel N*, Majumdar SR, Biggs C, Tsuyuki RT. Community pharmacist initiated screening program for osteoporosis: Randomized controlled trial. Osteoporosis Int 2010;21:391-398.